We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Lixisenatideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Lixisenatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2012–2019 with a typical study size of 495 participants.
Based on 11 studies · 6 meta-analyses · 5 RCTs · 8,042 total participants
Confidence
HighBy outcome
Lixisenatide has an evidence score of 5/10 — moderate evidence based on 11 indexed studies, including 6 meta-analyses. An FDA-approved once-daily GLP-1 receptor agonist (brand Adlyxin in the US, Lyxumia elsewhere) for type 2 diabetes. Honest appraisal: a short-acting, prandial GLP-1 with modest efficacy — it lowers HbA1c by roughly half a percentage point and produces only small weight loss, with its main strength being post-meal glucose control. Its cardiovascular-outcomes trial (ELIXA) was NEUTRAL: no increase but also no reduction in cardiovascular events. It is a real prescription medicine, not a supplement, and is now largely superseded by stronger weekly GLP-1s (semaglutide, dulaglutide). Included for reference only — not auto-recommended. Representative study: PMID 31422062.
The commonly studied dose of Lixisenatide is Prescription-only, clinician-directed. Subcutaneous 20 µg once daily within the hour before the first meal of the day, after a 10 µg starting dose for 14 days. DO NOT self-dose.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 11 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Lixisenatide (GLP-1 receptor agonist)
An FDA-approved once-daily GLP-1 receptor agonist (brand Adlyxin in the US, Lyxumia elsewhere) for type 2 diabetes. Honest appraisal: a short-acting, prandial GLP-1 with modest efficacy — it lowers HbA1c by roughly half a percentage point and produces only small weight loss, with its main strength being post-meal glucose control. Its cardiovascular-outcomes trial (ELIXA) was NEUTRAL: no increase but also no reduction in cardiovascular events. It is a real prescription medicine, not a supplement, and is now largely superseded by stronger weekly GLP-1s (semaglutide, dulaglutide). Included for reference only — not auto-recommended.
Scored 'Moderate' (5) because large phase-3 RCTs and meta-analyses prove real but modest glycemic efficacy, while its cardiovascular outcomes trial was neutral and weight loss is minimal — weaker than other GLP-1 agonists.
Lixisenatide is a short-acting, once-daily analogue of the gut incretin hormone GLP-1 (glucagon-like peptide-1).
It is a prescription drug, NOT a dietary supplement: marketed as Adlyxin (US) and Lyxumia (EU and elsewhere), given by once-daily subcutaneous injection (20 µg) for type 2 diabetes, and developed by Sanofi (first global approval 2013).
Mechanistically it activates the GLP-1 receptor, which stimulates glucose-dependent insulin secretion, suppresses glucagon, and — most distinctively for a short-acting agent — markedly delays gastric emptying.
Because its receptor activation is short-lived (prandial) rather than continuous, lixisenatide lowers POST-MEAL (postprandial) glucose more than fasting glucose, which sets it apart from longer-acting GLP-1s like liraglutide and semaglutide. The honest evidence picture is one of MODEST efficacy.
The phase-3 GetGoal program (a series of randomized placebo-controlled trials as monotherapy and as add-on to oral agents, pioglitazone, or basal insulin) consistently showed HbA1c reductions of roughly -0.4% to -0.7% versus placebo, pronounced reductions in 2-hour postprandial glucose, and only small weight changes (typically about -0.4 to -0.9 kg, or no weight gain).
A pooled GetGoal meta-analysis found a 76-week HbA1c reduction of -0.41% and a body-weight reduction of only -0.40 kg. Head-to-head (GetGoal-X) it was non-inferior to twice-daily exenatide on HbA1c with better GI tolerability.
The cardiovascular-outcomes trial ELIXA (6,068 patients with type 2 diabetes and a recent acute coronary syndrome) is the key honesty point: lixisenatide was NEUTRAL — non-inferior but NOT superior to placebo for major cardiovascular events (hazard ratio 1.02, 95% CI 0.89-1.17), with no reduction in heart failure hospitalization or death.
This contrasts with the cardiovascular BENEFIT later shown for liraglutide, semaglutide, and dulaglutide. Class meta-analyses that pool all GLP-1 cardiovascular-outcome trials show an overall ~12% MACE reduction, but lixisenatide itself contributed a neutral result.
The most common adverse effects are gastrointestinal (nausea, vomiting), and a thyroid C-cell tumor class warning and pancreatitis caution apply as for other GLP-1 receptor agonists.
Overall, lixisenatide is a real, approved drug with genuine but modest glycemic efficacy, a neutral cardiovascular profile, and limited weight benefit — and it has been largely superseded in practice by more potent once-weekly GLP-1 agonists.
A short-acting, prandial analogue of the incretin hormone GLP-1 that binds and activates the GLP-1 receptor. Unlike continuous long-acting GLP-1s, its receptor activation is short-lived — the upstream target that drives all downstream effects, biased toward post-meal glucose.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk.
Strongly slows gastric emptying — the dominant mechanism behind its pronounced postprandial-glucose lowering, and also the reason nausea is its most common adverse effect.
Acts on appetite circuits to reduce food intake, but as a short-acting agent the weight effect is small — typically minor weight loss or prevention of weight gain rather than the substantial loss seen with potent weekly GLP-1s.
How Lixisenatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription-only, clinician-directed. Subcutaneous 20 µg once daily within the hour before the first meal of the day, after a 10 µg starting dose for 14 days. DO NOT self-dose.
Loading: Start at 10 µg once daily for 14 days, then increase to the 20 µg once-daily maintenance dose — done under clinician supervision to limit GI side effects.
Can be taken without food
| Form | Type |
|---|---|
| 💊Subcutaneous once-daily injection (Adlyxin / Lyxumia) | Recommended |
| 💊Longer-acting once-weekly GLP-1 agonists (e.g. semaglutide, dulaglutide) — generally more potent | Alternative |
Lixisenatide is a short-acting, prandial GLP-1. In current practice it has largely been superseded by more potent once-weekly GLP-1 agonists that also carry proven cardiovascular benefit. Avoid grey-market/compounded GLP-1 products — use only pharmacy-dispensed product under prescription.
Minimum: 12 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Once daily within the hour before the first meal of the day. Dose is titrated upward by a clinician (10 µg then 20 µg) — never self-escalate.
Dose-response data unavailable. The current published research for Lixisenatide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Consistent but modest HbA1c reductions of roughly -0.4% to -0.7% vs placebo across the GetGoal phase-3 program; non-inferior to twice-daily exenatide.
Its standout effect: large reductions in 2-hour post-meal glucose and glucose excursion (driven by delayed gastric emptying), greater than longer-acting GLP-1s on this specific measure.
Only minor weight loss (~0.4-0.9 kg) or prevention of weight gain — much less than potent weekly GLP-1s. Not a meaningful weight-loss agent.
In the ELIXA outcomes trial after acute coronary syndrome, lixisenatide neither increased NOR reduced major cardiovascular events (HR 1.02) — cardiovascular-safe but without the benefit seen for liraglutide/semaglutide/dulaglutide.
Nausea and vomiting are the most frequent adverse events — usually mild and transient, and somewhat less than twice-daily exenatide; a common reason for discontinuation.
Avoid — GLP-1 class warning for thyroid C-cell tumors.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Not recommended — limited data; no dose adjustment needed for mild-to-moderate impairment but monitor.
Contraindicated — discontinue before a planned pregnancy.
Combining with basal insulin or sulfonylureas raises hypoglycemia risk; the clinician typically reduces those agents. Lixisenatide alone is low-hypoglycemia (glucose-dependent action).
Marked delay of gastric emptying can change the absorption of co-administered oral drugs (e.g. oral contraceptives, antibiotics); clinician monitoring and timing adjustments advised.
Tip: Gradual dose titration (10 µg then 20 µg); smaller meals; usually transient as the body adapts
Tip: Slow titration, hydration; report severe/persistent symptoms to a clinician
Tip: Clinician reduces background insulin/sulfonylurea dose; monitor blood glucose
Tip: Rotate injection sites; report rash, swelling, or systemic allergic symptoms
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
The best time to take Lixisenatide is in the morning. It can be taken on an empty stomach. Given once daily by subcutaneous injection within the hour before the first meal of the day (prandial dosing), because its main benefit is blunting the post-meal glucose rise.
Lixisenatide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, vomiting / diarrhea, symptomatic hypoglycemia (mainly with insulin/sulfonylurea). Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 class C-cell tumor warning; Multiple Endocrine Neoplasia syndrome type 2 (MEN2); Prior serious hypersensitivity to lixisenatide or any GLP-1 receptor agonist.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Do not combine with another GLP-1 agonist (e.g. liraglutide, dulaglutide, semaglutide, exenatide) — additive risk with no added benefit.